Lexicon Pharmaceuticals to Present at the Bank of America Health Care Conference
May 23 2007 - 7:30AM
PR Newswire (US)
THE WOODLANDS, Texas, May 23 /PRNewswire-FirstCall/ -- Lexicon
Pharmaceuticals, Inc. (NASDAQ:LXRX) today announced that Arthur T.
Sands, M.D., Ph.D., Lexicon's president and chief executive
officer, will present at the Bank of America Health Care Conference
at the Four Seasons Hotel in Las Vegas, Nevada on Friday, June 1,
2007 at 9:20 a.m. Pacific Time. A live webcast of Lexicon's
presentation may be accessed on its corporate website at
http://www.lexpharma.com/. An archived version of the webcast will
be available on the website through June 11, 2007. About Lexicon
Lexicon is a biopharmaceutical company focused on the discovery and
development of breakthrough treatments for human disease. Lexicon
currently has clinical programs underway for such areas of major
unmet medical need as irritable bowel syndrome and cognitive
disorders. The company has used its proprietary gene knockout
technology to discover more than 100 promising drug targets and
create an extensive pipeline of clinical and preclinical programs
in the therapeutic areas of diabetes and obesity, cardiovascular
disease, psychiatric and neurological disorders, cancer, immune
system disorders and ophthalmic disease. To advance the development
and commercialization of its programs, Lexicon is working both
independently and through collaborators including Bristol-Myers
Squibb Company, Genentech, Inc., N.V. Organon and Takeda
Pharmaceutical Company Limited. For additional information about
Lexicon and its programs, please visit http://www.lexpharma.com/.
Safe Harbor Statement This press release contains "forward-looking
statements," including statements relating to Lexicon's growth and
future operating results, discovery and development of products,
strategic alliances and intellectual property, as well as other
matters that are not historical facts or information. All
forward-looking statements are based on management's current
assumptions and expectations and involve risks, uncertainties and
other important factors, specifically including those relating to
Lexicon's ability to successfully conduct preclinical and clinical
development of its potential drug candidates, advance additional
candidates into preclinical and clinical development, obtain
necessary regulatory approvals, achieve its operational objectives,
obtain patent protection for its discoveries and establish
strategic alliances, as well as additional factors relating to
manufacturing, intellectual property rights, and the therapeutic or
commercial value of its drug candidates, that may cause Lexicon's
actual results to be materially different from any future results
expressed or implied by such forward-looking statements.
Information identifying such important factors is contained under
"Factors Affecting Forward-Looking Statements" and "Risk Factors"
in Lexicon's annual report on Form 10-K for the year ended December
31, 2006, as filed with the Securities and Exchange Commission.
Lexicon undertakes no obligation to update or revise any such
forward-looking statements, whether as a result of new information,
future events or otherwise. DATASOURCE: Lexicon Pharmaceuticals,
Inc. CONTACT: Bobbie Faulkner, Manager, Investor Relations of
Lexicon Pharmaceuticals, Inc., +1-281-863-3503, Web site:
http://www.lexpharma.com/
Copyright
Lexicon Pharmaceuticals (NASDAQ:LXRX)
Historical Stock Chart
From Jun 2024 to Jul 2024
Lexicon Pharmaceuticals (NASDAQ:LXRX)
Historical Stock Chart
From Jul 2023 to Jul 2024